Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$20.17 -2.9%	$21.69	$15.47 ▼ $36.37	$710.59M	1.2	228,219 shs	341,967 shs
CDXC ChromaDex		$6.16	$2.41 ▼ $9.18	$611.50M	2.21	816,251 shs	554,788 shs
CVAC CureVac	$5.41 -0.7%	$4.49	$2.37 ▼ $5.72	$1.22B	2.53	783,645 shs	883,637 shs
KRRO Korro Bio	$12.58 -5.8%	$13.98	$10.29 ▼ $98.00	$125.36M	2.43	106,601 shs	81,788 shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	0.00%	-9.41%	-11.76%	+24.95%	+11.59%
CDXC ChromaDex	0.00%	0.00%	0.00%	0.00%	+213.35%
CVAC CureVac	0.00%	+0.28%	+22.34%	+103.58%	+63.98%
KRRO Korro Bio	0.00%	+7.23%	-11.58%	-13.60%	-64.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	1.7212 of 5 stars	3.6	2.0	0.0	1.8	0.8	0.0
CDXC ChromaDex	3.1726 of 5 stars	3.5	0.0	4.0	0.0	0.0	1.9
CVAC CureVac	4.4942 of 5 stars	4.1	5.0	4.9	0.0	0.0	1.3
KRRO Korro Bio	1.686 of 5 stars	3.6	3.0	0.0	0.0	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$40.00	98.31% Upside
CDXC ChromaDex	3.00	Buy	$9.03	∞ Upside
CVAC CureVac	2.20	Hold	$6.83	26.31% Upside
KRRO Korro Bio	3.29	Buy	$102.43	714.22% Upside

Current Analyst Ratings Breakdown

Latest KRRO, AVBP, CVAC, and CDXC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	CVAC CureVac	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Neutral	$12.00 ➝ $5.50
6/24/2025	AVBP ArriVent BioPharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$39.00 ➝ $44.00
6/24/2025	AVBP ArriVent BioPharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00
6/13/2025	CVAC CureVac	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$7.00 ➝ $5.00
6/12/2025	CVAC CureVac	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform
6/12/2025	CVAC CureVac	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/28/2025	CVAC CureVac	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$10.00
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00
5/14/2025	AVBP ArriVent BioPharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/13/2025	KRRO Korro Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00 ➝ $25.00
5/13/2025	KRRO Korro Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$155.00 ➝ $90.00

(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	$7.65 per share	N/A
CDXC ChromaDex	$99.60M	0.00	N/A	N/A	$0.38 per share	0.00
CVAC CureVac	$579.18M	2.10	$0.87 per share	6.24	$3.36 per share	1.61
KRRO Korro Bio	$2.27M	52.04	N/A	N/A	$17.12 per share	0.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$80.49M	-$3.77	N/A	N/A	N/A	N/A	-49.21%	-46.61%	8/13/2025 (Estimated)
CDXC ChromaDex	-$4.94M	$0.10	787.29	0.00	N/A	1.62%	4.85%	2.70%	N/A
CVAC CureVac	$175.50M	$0.92	5.88	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
KRRO Korro Bio	-$83.58M	-$9.44	N/A	N/A	N/A	N/A	-51.64%	-37.94%	8/12/2025 (Estimated)

Latest KRRO, AVBP, CVAC, and CDXC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/7/2025	Q1 2025	KRRO Korro Bio	-$2.60	-$2.49	+$0.11	-$2.49	$0.13 million	$2.55 million
4/10/2025	Q4 2024	CVAC CureVac	-$0.14	-$0.15	-$0.01	-$0.15	$6.40 million	$15.44 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
CDXC ChromaDex	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
KRRO Korro Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	14.34	14.34
CDXC ChromaDex	N/A	2.95	2.35
CVAC CureVac	0.05	7.65	7.64
KRRO Korro Bio	N/A	9.41	9.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
CDXC ChromaDex	15.41%
CVAC CureVac	17.26%
KRRO Korro Bio	13.18%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	18.58%
CDXC ChromaDex	9.64%
CVAC CureVac	N/A
KRRO Korro Bio	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	27.86 million	N/A
CDXC ChromaDex	120	77.75 million	69.02 million	Optionable
CVAC CureVac	880	224.34 million	N/A	Optionable
KRRO Korro Bio	70	9.39 million	8.96 million	No Data

KRRO, AVBP, CVAC, and CDXC Headlines

Recent News About These Companies

Korro Bio, Inc. (NASDAQ:KRRO) Receives $102.43 Average Target Price from Brokerages

July 1, 2025 | americanbankingnews.com

Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of "Buy" by Analysts

June 28, 2025 | marketbeat.com

Cantor Fitzgerald Predicts Korro Bio FY2026 Earnings

June 10, 2025 | marketbeat.com

Korro to Participate in Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Veracyte (VCYT), Schrodinger (SDGR) and Korro Bio (KRRO)

May 14, 2025 | theglobeandmail.com

Korro Bio to Cut 20% of Workforce

May 7, 2025 | marketwatch.com

Korro Bio to Cut 20% of Workforce

May 7, 2025 | marketwatch.com

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

May 7, 2025 | globenewswire.com

Cantor Fitzgerald Initiates Coverage of Korro Bio (KRRO) with Overweight Recommendation

April 30, 2025 | msn.com

Chardan Capital Initiates a Buy Rating on Korro Bio (KRRO)

April 17, 2025 | markets.businessinsider.com

Korro Bio initiated with a Buy at Chardan

April 17, 2025 | markets.businessinsider.com

Chardan Capital Initiates Coverage of Korro Bio (KRRO) with Buy Recommendation

April 17, 2025 | msn.com

Piper Sandler Sticks to Their Buy Rating for Korro Bio (KRRO)

April 11, 2025 | markets.businessinsider.com

Korro Bio appoints Loic Vincent as Chief Scientific Officer

April 2, 2025 | markets.businessinsider.com

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

April 1, 2025 | globenewswire.com

Korro Bio: Promising Early Stage RNA Editing Company

March 28, 2025 | seekingalpha.com

Korro Bio Reports 2024 Financial Results and Progress

March 20, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX) and Korro Bio (KRRO)

March 20, 2025 | markets.businessinsider.com

Korro Bio, Inc.: Korro Reports Full Year 2024 Financial Results and Provides Business Updates

March 19, 2025 | finanznachrichten.de

Is Korro Bio (NASDAQ:KRRO) In A Good Position To Invest In Growth?

March 19, 2025 | uk.finance.yahoo.com

RBC Capital Remains a Buy on Korro Bio (KRRO)

March 19, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO, AVBP, CVAC, and CDXC Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$20.17 -0.60 (-2.89%)

As of 04:00 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

ChromaDex NASDAQ:CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

CureVac NASDAQ:CVAC

$5.41 -0.04 (-0.73%)

Closing price 04:00 PM Eastern

Extended Trading

$5.38 -0.03 (-0.55%)

As of 07:52 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Korro Bio NASDAQ:KRRO

$12.58 -0.77 (-5.77%)

As of 04:00 PM Eastern

Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time